var title_f26_32_27136="Toupet fundoplication";
var content_f26_32_27136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Toupet fundoplication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Toupet fundoplication is a partial fundoplication creating a collar of approximately 270&deg; around the esophagus posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27136=[""].join("\n");
var outline_f26_32_27136=null;
var title_f26_32_27137="Benzoin: Drug information";
var content_f26_32_27137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benzoin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benz-Protect Swabs&trade; [OTC];",
"     </li>",
"     <li>",
"      Sprayzoin&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F139977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Topical;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F139972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin protectant: Topical: Apply 1-2 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F139976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F139973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tincture, topical: Benzoin Compound USP: Benzoin 10% (30 mL, 59 mL, 60 mL, 120 mL, 473 mL); Benzoin NFXI (59 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Benz-Protect Swabs&trade;: Benzoin Compound USP: Benzoin 10% (3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tincture, topical [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sprayzoin&trade;: Benzoin Compound USP: Benzoin 10% (120 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protective application for irritations of the skin; sometimes used in boiling water as steam inhalants for its expectorant and soothing action",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8809 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27137=[""].join("\n");
var outline_f26_32_27137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139971\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139977\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139972\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139976\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139973\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139967\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139960\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139968\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298842\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218370\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8809\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8809|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_32_27138="Cysteine: Pediatric drug information";
var content_f26_32_27138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cysteine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/8/24707?source=see_link\">",
"    see \"Cysteine: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Added as a fixed ratio to crystalline amino acid solution: 40 mg cysteine per g of amino acids; dosage will vary with the daily amino acid dosage (eg, 0.5-2.5 g/kg/day amino acids would result in 20-100 mg/kg/day cysteine); individual doses of cysteine of 0.8-1 mmol/kg/day have also been added directly to the daily PN solution; the duration of treatment relates to the need for PN",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/8/24707?source=see_link\">",
"      see \"Cysteine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infants: Added as a fixed ratio to crystalline amino acid solution: 40 mg cysteine per g of amino acids; dosage will vary with the daily amino acid dosage (eg, 0.5-2.5 g/kg/day amino acids would result in 20-100 mg/kg/day cysteine); individual doses of cysteine of 0.8-1 mmol/kg/day have also been added directly to the daily PN solution; the duration of treatment relates to the need for PN; patients on chronic PN therapy have received cysteine until 6 months of age and in some cases until 2 years of age",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 50 mg/mL (10 mL, 50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Use only after dilution into PN solution; dilute with amino acid solution in a ratio of 40 mg cysteine to 1 g amino acid: eg, 500 mg cysteine is added to 12.5 g (250 mL) of 5% amino acid solution",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid excessive heat, do not freeze; when combined with parenteral amino acid solutions, cysteine is relatively unstable; it is intended to be added immediately prior to administration to the patient; infusion of the admixture should begin within 1 hour of mixing or refrigerated until use; stable 24 hours in PN solution; opened vials must be used within 4 hours of entry",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supplement to crystalline amino acid solutions, in particular the specialized pediatric formulas (eg, Aminosyn&reg; PF, TrophAmine&reg;) to meet the intravenous amino acid nutritional requirements of infants receiving parenteral nutrition (PN)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F155956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metabolic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Erythema, phlebitis, thrombosis, warm sensation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Azotemia, BUN increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cysteine or any component; patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal dysfunction and hepatic insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metabolic acidosis has occurred in infants related to the &ldquo;hydrochloride&rdquo; component of cysteine; each 1 mmol cysteine (175 mg) delivers 1 mEq chloride and 1 mEq hydrogen ion; to balance the extra hydrochloride ions and prevent acidosis, addition to the PN solution of a 1 mEq acetate electrolyte salt for each mmol (175 mg) of cysteine may be needed; each 40 mg cysteine (equal to every 1 g amino acid when used in the recommended ratio) adds 0.228 mEq chloride and hydrogen",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cysteine is generally considered to be a nonessential amino acid in adults because it can be synthesized from methionine (an essential amino acid). The RDA for methionine + cysteine is increased in pregnant women (IOM, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BUN, ammonia, electrolytes, pH, acid-base balance, serum creatinine, liver function tests, growth curve",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cysteine is a sulfur-containing amino acid synthesized from methionine via the transulfuration pathway. It is a precursor of the tripeptide glutathione and also of taurine. Newborn infants have a relative deficiency of the enzyme necessary to affect this conversion. Cysteine may be considered an essential amino acid in infants.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1057617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Addition of cysteine to PN solutions enhances the solubility of calcium and phosphate by lowering the overall pH of the solution",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13196 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-125.69.132.100-B0D0D57A02-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27138=[""].join("\n");
var outline_f26_32_27138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057611\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442276\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057607\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155939\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155928\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057614\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057609\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057613\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155956\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057616\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057606\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057605\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079852\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057610\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057604\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057617\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13196\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13196|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/8/24707?source=related_link\">",
"      Cysteine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_32_27139="Ocriplasmin: Drug information";
var content_f26_32_27139=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ocriplasmin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/24/4483?source=see_link\">",
"    see \"Ocriplasmin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15898399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Jetrea&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15387675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent;",
"     </li>",
"     <li>",
"      Vitreolytic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16032069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Symptomatic vitreomacular adhesion:",
"     </b>",
"     Intravitreal: 0.125 mg once (as a single dose to the affected eye)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16032070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16032071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16032072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15898400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, intravitreal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jetrea&reg;: 2.5 mg/mL (0.2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16032002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16032073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intravitreal: For intravitreal injection only. Must be diluted prior to use. Controlled aseptic conditions should be established prior to administration. After reconstitution, remove contents from vial using a syringe with a sterile, 19-gauge needle. Discard 19-gauge needle and replace with a sterile 30-gauge needle for intravitreal injection procedure (do not use 19-gauge needle for intravitreal injection). Depress plunger to expel excess air and medication (plunger tip should align with the 0.1 mL marking on syringe). Insert the injection needle 3.5-4 mm posterior to the limbus aiming toward the center of the vitreous cavity, avoiding the horizontal meridian, then deliver the 0.1 mL injection (corresponds to 0.125 mg ocriplasmin) into the mid-vitreous. Adequate anesthesia and a broad-spectrum antimicrobial agent should be administered prior to the procedure. Only one eye should be treated with each vial. Treatment of a patient&rsquo;s contralateral eye requires a new vial and administration supplies and is not recommended within 7 days of the first injection. Repeated administration to the same eye is not recommended. Each vial should only be used as a single injection for the treatment of one eye.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15387659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptomatic vitreomacular adhesion (VMA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16032001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Jetrea: Brand name for ocriplasmin [U.S.] may be confused with Jetrex brand name for dextromethorphan, guaifenesin, bromhexine and chlorpheniramine maleate [India]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16027540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Ocular: Blurred vision (5% to 20%), conjunctival hemorrhage (5% to 20%), eye pain (5% to 20%), macular hole (5% to 20%), photopsia (5% to 20%), retinal edema (5% to 20%), visual acuity decreased (5% to 20%; &ge;3-line decrease 6%), visual impairment (5% to 20%), vitreous floaters (5% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Ocular: Intraocular inflammation (7%), anterior chamber cell (2% to 5%), cataract (2% to 5%), conjunctival hyperemia (2% to 5%), dry eyes (2% to 5%), intraocular pressure increased (2% to 5%), iritis (2% to 5%), macular edema (2% to 5%), metamorphopsia (2% to 5%), ocular discomfort (2% to 5%), photophobia (2% to 5%), retinal degeneration (2% to 5%), vitreous detachment (2% to 5%), dyschromatopsia (2%), a-wave and b-wave amplitude decreased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Lens subluxation (high dose; 0.175 mg), retinal detachment",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16032007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16032008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Decreased vision: May cause decreased visual acuity as a result of condition progression with traction, which may require surgical intervention. Monitor visual acuity appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dyschromatopsia: May cause dyschromatopsia, described as yellowish vision, following injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Intravitreal injection procedure associated effects: Intraocular inflammation, infection, hemorrhage, or increased intraocular pressure may result after intravitreal injection. In clinical trials, intraocular inflammation occurred at a higher rate with ocriplasmin when compared to placebo; intraocular inflammation events were typically mild and transient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lens subluxation: Administration of higher than recommended doses may result in lens subluxation (1 case report).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Retinal breaks: After ocriplasmin administration, retinal detachment or retinal tear (with or without retinal detachment) may occur before, during, or after future vitrectomy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16061141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16061139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16032003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16032004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Systemic exposure following a single intravitreal injection is expected to be low.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16032005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16032006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic exposure following a single intravitreal injection is expected to be low.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Jetrea Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/0.2 mL (0.2 mL): $4740.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16032086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following intravitreal injection, monitor for elevation in intraocular pressure, signs of endophthalmitis, retinal detachment, or decreased vision.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16032013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ocriplasmin is a recombinant form of human plasmin that acts as a proteolytic within the vitreous body and vitreoretinal interface. Protein matrix components responsible for the vitreomacular adhesion (eg, laminin, fibronectin, and collagen) are lysed by ocriplasmin.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16032015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Detectable levels in systemic circulation are not expected",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Endogenous protein catabolism pathway; rapidly inactivated by protease inhibitor alpha-2-antiplasmin or alpha-2-macroglobulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     &lt;3% of the administered dose is detected in vitreous fluid 24 hours after administration.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Stalmans P, Benz MS, Gandorfer A, et al, &ldquo;Enzymatic Vitreolysis With Ocriplasmin for Vitreomacular Traction and Macular Holes,&rdquo;",
"      <i>",
"       N Engl J Med,",
"      </i>",
"      2012, 367(7):606-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/32/27139/abstract-text/22894573/pubmed\" id=\"22894573\" target=\"_blank\">",
"        22894573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86876 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27139=[""].join("\n");
var outline_f26_32_27139=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15898399\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15387675\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032069\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032070\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032071\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032072\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15898400\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032002\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032073\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15387659\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032001\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16027540\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032007\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032008\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16061141\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16061139\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032003\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032004\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032005\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032006\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570457\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032086\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032013\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032015\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86876\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86876|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/24/4483?source=related_link\">",
"      Ocriplasmin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_32_27140="Classification of autoimmune hepatitis";
var content_f26_32_27140=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of autoimmune hepatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/32/27140/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27140/contributors\">",
"     Michael A Heneghan, MD, MMedSc, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/32/27140/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27140/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/32/27140/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27140/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/32/27140/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hepatitis is a chronic hepatitis which can progress to cirrhosis. It is characterized by autoimmune features, hyperglobulinemia, and the presence of circulating autoantibodies. Most cases respond to therapy with immunomodulating drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link\">",
"     \"Treatment of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since it was first described in the 1950s, this disorder has been known by a variety of terms, including active chronic hepatitis, chronic active hepatitis, chronic aggressive hepatitis, lupoid hepatitis, plasma cell hepatitis, and, most commonly, autoimmune chronic active hepatitis. In 1992, the International Autoimmune Hepatitis Group recommended autoimmune hepatitis as the most appropriate and least redundant term for this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmune hepatitis is characterized by considerable heterogeneity, as illustrated by the variety of clinical features, histologic findings, immunogenetic phenotypes, and circulating autoantibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"    </a>",
"    .) Since the discovery of a distinct form of autoimmune hepatitis seen primarily in children and young adults that is generally characterized by antibodies to a specific cytochrome P450 (IID6) located in liver and kidney microsomes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/2\">",
"     2",
"    </a>",
"    ], a classification of autoimmune hepatitis based upon circulating autoantibodies has been proposed.",
"   </p>",
"   <p>",
"    Although extensions of this autoantibody-based classification have been proposed from time to time, none has proven to provide a valid, clinically useful classification for predicting disease course or response to treatment. In addition, there is little evidence to support a role for these antibodies in the pathogenesis of this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19590?source=see_link\">",
"     \"Pathogenesis of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the classification of autoimmune hepatitis, while its diagnosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"    </a>",
"    .) This topic is also discussed in a guideline issued by the American Association for the Study of Liver Diseases. This guideline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/3\">",
"     3",
"    </a>",
"    ] can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current classification of autoimmune hepatitis according to the type of autoantibodies present is depicted in the table (",
"    <a class=\"graphic graphic_table graphicRef65135 \" href=\"UTD.htm?8/0/8203\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The characteristics of the major antibodies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42902?source=see_link\">",
"     \"Serologic markers of autoimmune hepatitis\"",
"    </a>",
"    .) Two major forms have been described, type 1 and type 2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Type 1 autoimmune hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1, or classic autoimmune hepatitis, is characterized by circulating antibodies to nuclei (ANA)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    smooth muscle (ASMA); the latter are thought to be reflective of more specific anti-actin antibodies (AAA). ASMA titers of 1:320 or greater generally reflect the presence of AAA. IgG anti F actin AAA measured by ELISA appear to be more sensitive than ASMA measured by immunofluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/5\">",
"     5",
"    </a>",
"    ], but in some cases ASMA are found in the absence of AAA.",
"   </p>",
"   <p>",
"    In addition, antibodies to soluble liver antigens (SLA) occur in approximately 10 to 30 percent of patients with type 1 and type 2 autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/6\">",
"     6",
"    </a>",
"    ]. When SLA antibodies were first described, they were incorrectly thought to represent a distinct third form of autoimmune hepatitis. However, it now appears that a variety of antibodies appear in the two major forms of the disease, but SLA antibodies are the most specific. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19590?source=see_link\">",
"     \"Pathogenesis of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other antibodies described in type 1 autoimmune hepatitis include those directed against DNA (including double-stranded DNA), Saccharomyces cerevisiae (ASCA), a plasma-membrane sulfatide, the nuclear envelope proteins lamins A and C, a number of cytoskeleton antigens, and antineutrophil cytoplasmic antibodies (ANCA), which characterize primary sclerosing cholangitis and inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. ANCA are commonly present in type 1 but not type 2 autoimmune hepatitis; they have a P-ANCA pattern on immunofluorescence and are directed against a myeloid 50 kilodalton nuclear envelope protein rather than myeloperoxidase with typical ANCA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .) On occasion, they appear as isolated antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating antibodies against the liver-specific asialoglycoprotein receptor are found in a large percentage of European, Asian, and North American patients with autoimmune hepatitis. At present, these antibodies serve primarily as a research tool [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On occasion, antimitochondrial antibodies (AMA), which are generally seen in primary biliary cirrhosis, accompany ANA, SLA,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ASMA in autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. In contrast, the isolated presence of AMA almost always signifies primary biliary cirrhosis, except in those rare instances in which an overlap syndrome occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/4,12\">",
"     4,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type 2 autoimmune hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 autoimmune hepatitis is defined by the presence of antibodies to",
"    <span class=\"nowrap\">",
"     liver/kidney",
"    </span>",
"    microsomes (ALKM-1), which are directed at an epitope of CYP2D6 (cytochrome P450IID6),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibodies to a liver cytosol antigen (ALC-1 or LC1) and to SLA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/2,13,14\">",
"     2,13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42902?source=see_link\">",
"     \"Serologic markers of autoimmune hepatitis\"",
"    </a>",
"    .) On occasion, type 2 autoimmune hepatitis may be marked exclusively by ALC-1.",
"   </p>",
"   <p>",
"    ALKM-2 antibodies, seen in ticrynafen-induced hepatitis, and ALKM-3 antibodies, seen in chronic delta hepatitis, are not characteristic of type 2 autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overlap syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with variant forms of autoimmune hepatitis have clinical and serologic findings of autoimmune hepatitis plus features of other forms of chronic liver disease, particularly primary biliary cirrhosis or primary sclerosing cholangitis. The taxonomy of these variants (also referred to as overlap syndromes) is controversial. Studies in children describe an overlap syndrome referred to as autoimmune sclerosing cholangitis in a higher proportion of patients than that seen in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35911?source=see_link\">",
"     \"Definition and treatment of variants of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also autoimmune conditions associated with elevated blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue levels of IgG4. Recognized IgG4-associated diseases include pancreatitis and cholangitis. IgG4-associated autoimmune hepatitis has also been proposed, but whether it represents a distinct entity is not yet clear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27140/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/56/25474?source=see_link\">",
"       \"Patient information: Autoimmune hepatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The current classification of autoimmune hepatitis according to the type of autoantibodies present is depicted in the table (",
"      <a class=\"graphic graphic_table graphicRef65135 \" href=\"UTD.htm?8/0/8203\">",
"       table 1",
"      </a>",
"      ). The characteristics of the major antibodies are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42902?source=see_link\">",
"       \"Serologic markers of autoimmune hepatitis\"",
"      </a>",
"      .) Two major forms of autoimmune hepatitis have been described, type 1 and type 2.",
"     </li>",
"     <li>",
"      Type 1, or classic autoimmune hepatitis, is characterized by circulating antinuclear antibodies (ANA)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anti-smooth muscle antibodies (ASMA) and anti-actin antibodies (AAA), although other autoantibodies may be present.",
"     </li>",
"     <li>",
"      Type 2 autoimmune hepatitis is defined by the presence of antibodies to",
"      <span class=\"nowrap\">",
"       liver/kidney",
"      </span>",
"      microsomes (ALKM-1), which are directed at an epitope of CYP2D6 (cytochrome P450IID6),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antibodies to a liver cytosol antigen (ALC-1 or LC1).",
"     </li>",
"     <li>",
"      Patients with variant forms of autoimmune hepatitis have clinical and serologic findings of autoimmune hepatitis plus features of other forms of chronic liver disease, particularly primary biliary cirrhosis or primary sclerosing cholangitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35911?source=see_link\">",
"       \"Definition and treatment of variants of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of autoimmune hepatitis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link\">",
"       \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10757830\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Edward Krawitt, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/1\">",
"      Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/2\">",
"      Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of \"autoimmune\" hepatitis. Hepatology 1987; 7:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/3\">",
"      Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/4\">",
"      Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/5\">",
"      Frenzel C, Herkel J, L&uuml;th S, et al. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol 2006; 101:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/6\">",
"      Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993; 105:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/7\">",
"      Reddy KR, Colombel JF, Poulain D, Krawitt EL. Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease. Am J Gastroenterol 2001; 96:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/8\">",
"      Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997; 25:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/9\">",
"      Terjung B, Spengler U, Sauerbruch T, Worman HJ. \"Atypical p-ANCA\" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/10\">",
"      Krawitt EL. Sudden jaundice with isolated atypical perinuclear antineutrophil cytoplasmic antibodies. Ann Intern Med 1999; 131:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/11\">",
"      Treichel U, McFarlane BM, Seki T, et al. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994; 107:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/12\">",
"      O'Brien C, Joshi S, Feld JJ, et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008; 48:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/13\">",
"      Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/14\">",
"      Bridoux-Henno L, Maggiore G, Johanet C, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004; 2:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/15\">",
"      Philipp T, Durazzo M, Trautwein C, et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994; 344:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27140/abstract/16\">",
"      Umemura T, Zen Y, Nakanuma Y, Kiyosawa K. Another cause of autoimmune hepatitis. Hepatology 2010; 52:389.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3663 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27140=[""].join("\n");
var outline_f26_32_27140=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Type 1 autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type 2 autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overlap syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10757830\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3663\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3663|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/0/8203\" title=\"table 1\">",
"      Classif autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35911?source=related_link\">",
"      Definition and treatment of variants of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19590?source=related_link\">",
"      Pathogenesis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/56/25474?source=related_link\">",
"      Patient information: Autoimmune hepatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42902?source=related_link\">",
"      Serologic markers of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_32_27141="Hydroxocobalamin (vitamin B12 supplement and cyanide antidote ): Pediatric drug information";
var content_f26_32_27141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxocobalamin (vitamin B12 supplement and cyanide antidote ): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"    see \"Hydroxocobalamin (vitamin B12 supplement and cyanide antidote ): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/49/1813?source=see_link\">",
"    see \"Hydroxocobalamin (vitamin B12 supplement and cyanide antidote ): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4090481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cyanokit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12785471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cyanokit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Cyanide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Water Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Congenital transcobalamin deficiency: 1000 mcg twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobalamin C disease: 1000 mcg/dose once daily was used in a single full-term neonate in conjunction with carnitine and folinic acid (Kind, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"      see \"Hydroxocobalamin (vitamin B12 supplement and cyanide antidote ): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cyanide toxicity:",
"     </b>",
"     Cyanokit&reg;: limited data available: I.V.: 70 mg/kg as a single infusion; maximum dose: 5000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      deficiency (pernicious anemia); treatment (uncomplicated disease):",
"     </b>",
"     I.M.: Initial: 100 mcg/day for 10-15 days (total dose: 1-5 mg); maintenance: 60 mcg/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      or as an alternative:",
"     </b>",
"     30-50 mcg/day for at least 2 weeks (total dose: 1-5 mg); maintenance: 100 mcg/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cyanide toxicity:",
"     </b>",
"     (Cyanokit&reg;): I.V.:  Initial: 5000 mg as single infusion; may repeat a second 5000 mg dose depending on the severity of poisoning and clinical response: maximum cumulative dose: 10 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      deficiency (pernicious anemia); treatment:",
"     </b>",
"     Varying regimens: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Uncomplicated disease: Initial: 30 mcg/day for 5-10 days; maintenance: 100-200 mcg/monthly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      or as an alternative:",
"     </b>",
"     1000 mcg/day for 5-10 days, followed by 100-200 mcg/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      or as an alternative:",
"     </b>",
"     100 mcg/day for 1 week, followed by 100 mcg every other day for 2 weeks; maintenance: 100 mcg/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Complicated disease (eg, severe anemia with heart failure, thrombocytopenia with bleeding, granulocytopenia with infection, severe neurologic damage): I.M.: 1000 mcg plus folic acid 15 mg once, followed by 100 mcg/day plus oral folic acid 5 mg/day for 1 week; maintenance dosing as above",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     <b>",
"      Dosage interval in hepatic or renal impairment:",
"     </b>",
"     A decrease in the interval between injections may be required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyanokit&reg;: 2.5 g [DSC], 5 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1000 mcg/mL (30 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes powder for injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Administer 1000 mcg/mL injection I.M. only; do not administer SubQ",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Cyanokit&reg;: Reconstitute 2.5 g vial with 100 mL NS (preferred), LR, or 5% dextrose; after reconstitution, repeatedly invert or \"rock\" solution for at least 30 seconds; do not shake. Administer over 15 minutes; if repeat dose is needed, administer second dose over 15 minutes to 2 hours depending upon the patient's clinical state",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F4010125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS (preferred), LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Incompatible",
"     </b>",
"     with ascorbic acid, blood products, sodium nitrite, sodium thiosulfate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for I.M. injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. infusion (Cyanokit&reg;): Prior to reconstitution, store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyanokit&reg; may be exposed at short intervals to temperatures outside of room temperature:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Usual transport: &le;15 days at 5&deg;C to 40&deg;C (41&deg;F to 104&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Desert transport: &le;4 days at 5&deg;C to 40&deg;C (41&deg;F to 104&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Freezing/defrosting cycles: &le;15 days at -20&deg;C to 40&deg;C (-4&deg;F to 104&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Reconstituted vials (Cyanokit&reg;) are stable for 6 hours at temperatures not exceeding 40&deg;C (104&deg;F). Hydroxocobalamin infusion (Cyanokit&reg;) is physically incompatible if mixed with diazepam, dobutamine, dopamine, fentanyl, nitroglycerin, pentobarbital, propofol, and thiopental. It is also chemically incompatible with sodium thiosulfate, sodium nitrate, and ascorbic acid. It should not be infused either in the same solution or into the same I.V. line with these medications.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M. injection: Treatment of pernicious anemia and other vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency states; dietary supplement particularly in conditions of increased requirements (eg, pregnancy, thyrotoxicosis, hemorrhage, malignancy, liver or kidney disease) [FDA approved in pediatric patients (all ages) and adults]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. infusion (Cyanokit&reg;): Treatment of cyanide poisoning (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F180773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.M. injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Exanthema (transient), itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (mild, transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, feeling of swelling of the entire body",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      I.V. infusion (Cyanokit&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Blood pressure increased, chest discomfort, hot flashes, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness, headache, memory impairment, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Angioneurotic edema (postmarketing reports), erythema (may last up to 2 weeks), pruritus, rash (predominantly acneiform; can appear 7-28 days after administration and usually resolves within a few weeks), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal discomfort, diarrhea, dyspepsia, dysphagia, hematochezia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Chromaturia (may last up to 5 weeks after administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Lymphocytes decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Infusion site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Irritation, redness, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dry throat, dyspnea, throat tightness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Allergic reaction (including anaphylaxis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxocobalamin, cyanocobalamin, cobalt, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When using solution for I.M. injection as treatment of severe vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency: Serum potassium concentrations should be monitored early as severe hypokalemia has occurred after the conversion of megaloblastic anemia to normal erythropoiesis; the increase in nucleic acid degradation produced by administration of hydroxocobalamin to deficient patients may result in gout in susceptible individuals; use of hydroxocobalamin in folic acid deficient individuals may improve folate-deficient megaloblastic anemia and obscure the true diagnosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anaphylactic shock has occurred after parenteral vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     administration; intradermal skin testing may be used prior to administration in individuals sensitive to cobalt",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When using Cyanokit&reg;: Increased blood pressure (&gt;180 mm Hg systolic or &gt;110 mm Hg diastolic) is associated with infusion; elevations usually noted at beginning of infusion, peak toward the end of infusion, and return to baseline within 4 hours of infusion. Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate. Treatment of cyanide poisoning should include decontamination and supportive therapy. Photosensitivity is a potential concern; avoid direct sunlight while skin remains discolored. Safety and efficacy for use in children has not been established. Will produce chromaturia which may last up to 5 weeks after administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F180720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4010117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies are insufficient to determine the effect, if any, on pregnancy or fetal development. There are no adequate and well-controlled studies in pregnant women. Data on the use of hydroxocobalamin in pregnancy for the treatment of cyanide poisoning and cobalamin defects are limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anemia and deficiency states: Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     , serum potassium, erythrocyte and reticulocyte counts, hemoglobin, hematocrit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanide toxicity: Blood pressure and heart rate during and after infusion, serum lactate levels, venous-arterial pO",
"     <sub>",
"      2",
"     </sub>",
"     gradient, blood cyanide concentrations",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1059325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     : Normal: 200-900 pg/mL; vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency: &lt;200 pg/mL; megaloblastic anemia: &lt;100 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanide toxicity: Blood cyanide levels may be used for diagnosis confirmation; however, reliable levels require prompt testing and proper storage conditions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanide levels related to clinical symptomatology:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tachycardia/flushing: 0.5-1 mg/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obtundation: 1-2.5 mg/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Coma: 2.5-3 mg/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Death: &gt;3 mg/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydroxocobalamin (vitamin B",
"     <sub>",
"      12a",
"     </sub>",
"     ) is a precursor to cyanocobalamin (vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     ). Cyanocobalamin acts as a coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis, used in cell replication and hematopoiesis. In the presence of cyanide, each hydroxocobalamin molecule can bind one cyanide ion by substituting it for the hydroxo ligand linked to the trivalent cobalt ion, forming cyanocobalamin.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Megaloblastic anemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Conversion of megaloblastic to normoblastic erythroid hyperplasia within bone marrow: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Increased reticulocytes: 2-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Complicated vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Psychiatric sequelae: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Thrombocytopenia: 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Granulocytopenia: 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Principally stored in the liver; also stored in the kidneys and adrenals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: I.M. solution: Bound to transcobalamin II; I.V.: Cyanokit&reg;: Significant; forms various cobalamin-(III) complexes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: I.V.: 26-31 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted in the tissues to active coenzymes methylcobalamin and deoxyadenosylcobalamin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (50% to 60% within initial 72 hours)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/49/1813?source=see_link\">",
"      see \"Hydroxocobalamin (vitamin B12 supplement and cyanide antidote ): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Life-long therapy is required in patients with pernicious anemia or other absorption defects; do not discontinue therapy without consulting your physician; avoid alcohol; large doses (Cyanokit&reg;) will result in red-colored urine for up to 5 weeks and skin and mucous membrane redness for up to 2 weeks after administration; may cause photosensitivity (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching) while skin is discolored; avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs; an acne-like rash may occur 7-28 days after administration of Cyanokit&reg;; this rash usually goes away without any treatment",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1059332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cyanocobalamin is preferred over hydroxocobalamin as a treatment agent for anemia due to reports of antibody formation to the hydroxocobalamin-transcobalamin complex. Cyanide is a clear colorless gas or liquid with a faint bitter almond odor. Cyanide reacts with trivalent ions in cytochrome oxidase in the mitochondria leading to histotoxic hypoxia and lactic acidosis. Signs and symptoms of cyanide toxicity include headache, altered mental status, dyspnea, mydriasis, chest tightness, nausea, vomiting, tachycardia/hypertension (initially), bradycardia/hypotension (later), seizures, cardiovascular collapse, or coma. Expert advice from a regional poison control center for appropriate use may be obtained (1-800-222-1222).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kind T, Levy J, Lee M, et al, \"Cobalamin C Disease Presenting as Hemolytic-Uremic Syndrome in the Neonatal Period,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2002, 24(4):327-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/32/27141/abstract-text/11972107/pubmed\" id=\"11972107\" target=\"_blank\">",
"        11972107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13365 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27141=[""].join("\n");
var outline_f26_32_27141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4090481\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12785471\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059323\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442605\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059316\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180723\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180710\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059327\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010125\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059319\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059326\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180773\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059331\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059315\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059314\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299483\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180718\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180720\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010117\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059322\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059325\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059313\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059329\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059330\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059321\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059332\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13365\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13365|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=related_link\">",
"      Hydroxocobalamin (vitamin B12 supplement and cyanide antidote ): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/49/1813?source=related_link\">",
"      Hydroxocobalamin (vitamin B12 supplement and cyanide antidote ): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_32_27142="Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection";
var content_f26_32_27142=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/32/27142/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27142/contributors\">",
"     Craig A Elmets, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/32/27142/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27142/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27142/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/32/27142/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27142/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/32/27142/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photosensitivity is an abnormal cutaneous response to ultraviolet radiation (UVR) and, in some individuals, visible light. Depending upon the type of photosensitivity disease, the abnormal response can manifest as macular erythema, papules, plaques, vesicles, bullae, telangiectasias, or eczematous patches. For some photosensitivity diseases, the rash may result in scarring. One of the key features in establishing the diagnosis of a photosensitive eruption is its distribution. In most instances, it occurs on sun-exposed areas of the skin; the face, ears, dorsal forearms, \"V\"-area of the neck and upper chest are commonly affected sites. However, occasionally it can occur on covered areas of the body, especially in individuals who use tanning beds.",
"   </p>",
"   <p>",
"    The principles of photobiology, evaluation of the photosensitive patient, and general recommendations for photoprotection in the photosensitive patient will be reviewed here. The diagnosis and treatment of specific photosensitivity conditions and sunburn are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20455?source=see_link\">",
"     \"Polymorphous light eruption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=see_link\">",
"     \"Sunburn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHOTOBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;UVR emitted from the sun is divided into three wavelength ranges: UVA (320 to 400 nm), UVB (290 to 320 nm), and UVC (200 to 290 nm). UVC is absorbed by the ozone layer in the atmosphere [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/1\">",
"     1",
"    </a>",
"    ]. Because of this, UVC does not reach the earth's surface and usually does not play a role in inducing photosensitivity. It is emitted by germicidal lamps and welding arcs and has been rarely reported to provoke photosensitivity in individuals with occupational exposure. UVA and some UVB penetrate the atmosphere and reach the earth's surface.",
"   </p>",
"   <p>",
"    Patients with photosensitivity may react to UVA, UVB, or visible light (400 to 760 nm) (",
"    <a class=\"graphic graphic_figure graphicRef70045 \" href=\"UTD.htm?15/8/15502\">",
"     figure 1",
"    </a>",
"    ). Longer wavelengths penetrate deeper into the skin. UVA passes through the epidermis and into the dermis, whereas UVB enters into the epidermis, but little reaches the dermis. UVR has multiple effects on the skin. Notably, UVR causes DNA damage and mutations, which are initiating events in skin carcinogenesis. UV-induced immunosuppression may also contribute to the development of skin cancers by interfering with the ability of the immune system to identify and eliminate neoplastic cells before they become clinically apparent skin cancers. A further effect of UVR is the generation of reactive oxygen species, such as singlet oxygen, superoxide anion and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    . The generation of reactive oxygen species leads, among other things, to lipid peroxidation, DNA damage and activation of signal transduction pathways. These effects have been implicated in the pathogenesis of skin cancer, photoaging, and inflammatory responses in photosensitivity disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION OF PATIENTS WITH PHOTOSENSITIVITY DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photosensitivity disorders of the skin are conditions in which an abnormal cutaneous response occurs after exposure to ultraviolet radiation or visible light. The major categories include idiopathic photodermatoses, photodermatoses due to exogenous or endogenous agents, photoexacerbated dermatoses, and photosensitive genodermatoses.",
"   </p>",
"   <p>",
"    A table describing the clinical and diagnostic findings of many of the disorders is provided (",
"    <a class=\"graphic graphic_table graphicRef57800 \" href=\"UTD.htm?15/1/15390\">",
"     table 1",
"    </a>",
"    ). Detailed discussions of these disorders are available separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20455?source=see_link\">",
"     \"Polymorphous light eruption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the photosensitive patient involves taking a thorough history and performing a complete skin examination. Phototesting and photopatch testing, as well as laboratory evaluation, are useful in certain cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history should include (",
"    <a class=\"graphic graphic_table graphicRef57800 \" href=\"UTD.htm?15/1/15390\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age of onset",
"     </li>",
"     <li>",
"      Length of time between exposure and the appearance of the eruption",
"     </li>",
"     <li>",
"      Duration of the eruption",
"     </li>",
"     <li>",
"      Location of the eruption",
"     </li>",
"     <li>",
"      Description of the eruption (useful in patients who present without active lesions)",
"     </li>",
"     <li>",
"      Symptoms (eg, pruritus, pain, burning, and stinging)",
"     </li>",
"     <li>",
"      Whether the eruption is induced by sun-exposure through window glass",
"     </li>",
"     <li>",
"      Seasonal variation",
"     </li>",
"     <li>",
"      Tanning bed use",
"     </li>",
"     <li>",
"      Family history of photosensitivity",
"     </li>",
"     <li>",
"      Medication history (current and past)",
"     </li>",
"     <li>",
"      History of products applied to skin (exposure to photosensitizers)",
"     </li>",
"     <li>",
"      Occupational and recreational activities",
"     </li>",
"     <li>",
"      Prior history of photoexacerbated dermatoses (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H31#H31\">",
"       \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Photoexacerbated dermatoses'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These features can be used to narrow the differential diagnosis of photosensitivity (",
"    <a class=\"graphic graphic_table graphicRef57800 \" href=\"UTD.htm?15/1/15390\">",
"     table 1",
"    </a>",
"    ). A report of childhood onset may suggest diagnoses such as hydroa vacciniforme, actinic prurigo, or erythropoietic protoporphyria. In contrast, chronic actinic dermatitis typically occurs in the elderly.",
"   </p>",
"   <p>",
"    A complaint of painful skin with sun exposure may suggest a diagnosis of erythropoietic protoporphyria instead of other photodermatoses that are characteristically pruritic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5801?source=see_link\">",
"     \"Congenital erythropoietic porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transient hive-like lesions appearing within minutes of sun exposure suggest solar urticaria rather than polymorphous light eruption (PMLE). PMLE typically appears hours to days after sun exposure, most commonly as papules and papulovesicles, and persists for days.",
"   </p>",
"   <p>",
"    A history of reaction to sunlight passing through window glass indicates a UVA-sensitive photodermatosis, because UVB, unlike UVA, does not penetrate through window glass. Patients often fail to distinguish between sun exposure and exposure to heat. Care must be taken to establish that UV, rather than heat, is responsible for provoking the disease.",
"   </p>",
"   <p>",
"    Review of the patient's medications is important in determining a drug-related cause. Details about outdoor activities, occupation, and recreation are helpful in distinguishing a true photosensitivity eruption from an airborne allergic contact dermatitis, irritant dermatitis, or arthropod bites. Lastly, a history of an underlying disease may bring a photoexacerbated disorder into the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H31#H31\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Photoexacerbated dermatoses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin examination should include both sun-exposed and unexposed areas. Photosensitive eruptions typically occur symmetrically on the face, ears, \"V\" area on the neck and chest, and extensor forearms. Sparing of the relatively shaded area of the upper lip, submental neck, upper eyelids, nasolabial folds, and post-auricular areas may be clues for a photosensitive eruption.",
"   </p>",
"   <p>",
"    Assessment of the type of lesions (eg, urticaria, papules, or vesicles) is essential. Key features for narrowing the differential diagnosis are often available (",
"    <a class=\"graphic graphic_table graphicRef57800 \" href=\"UTD.htm?15/1/15390\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory studies to be ordered are determined by the suspected photosensitivity disorder, based upon the history and physical examination findings. Laboratory evaluation may include ANA, anti-dsDNA, anti-Ro (SSA), anti-La (SSB) titers and porphyrin studies when lupus erythematosus or porphyria is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\", section on 'Laboratory testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link&amp;anchor=H14#H14\">",
"     \"Porphyrias: An overview\", section on 'Laboratory diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A skin biopsy may provide helpful information but requires correlation with clinical findings. Even in circumstances in which the skin biopsy is non-diagnostic, histology may be helpful in ruling out other diseases included in the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Phototesting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototesting, if available, can be used to determine a patient's minimal erythema dose (MED). The MED is the lowest dose of ultraviolet radiation delivered to the skin that induces erythema 24 hours after exposure.",
"   </p>",
"   <p>",
"    The MED can be helpful as a diagnostic tool. MEDs in patients with certain photodermatoses are lower than those in normal controls. Phototesting can also help to define the action spectrum of a photodermatosis (UVA versus UVB versus visible light). A summary of the results of phototesting in photosensitivity disorders is provided (",
"    <a class=\"graphic graphic_table graphicRef57800 \" href=\"UTD.htm?15/1/15390\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For phototesting, an opaque template with multiple openings and the appropriate light sources are used to irradiate separate areas of skin with progressively increasing doses of UVA, UVB, or visible light [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/3\">",
"     3",
"    </a>",
"    ]. An uninvolved site, typically the back or inner aspect of the forearm, is used as the test area. The lowest dose of radiation that provides uniform erythema over the irradiated site at 24 hours is the MED.",
"   </p>",
"   <p>",
"    In patients with solar urticaria, the minimal urticarial dose (MUD) is evaluated by administering increasing doses of UVA, UVB, or visible light and assessing the occurrence of urticarial lesions at the site of irradiation within the first hour [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to basic phototesting to determine the MED, provocation phototesting may be performed in an attempt to induce lesions. Provocation phototesting is primarily used for suspected PMLE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/5\">",
"     5",
"    </a>",
"    ]. The best results for PMLE are obtained when the tested site is in a location of previously affected skin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/3\">",
"     3",
"    </a>",
"    ]. Radiation doses that approximate the MED typically are administered repeatedly over three to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/3\">",
"     3",
"    </a>",
"    ]. The tested area is subsequently examined for occurrence of lesions. Skin biopsy and histologic examination may be required to confirm the diagnosis.",
"   </p>",
"   <p>",
"    Prior to phototesting, patients must discontinue glucocorticoids and other systemic immunosuppressants for at least two weeks and antihistamines for at least one to two days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/3\">",
"     3",
"    </a>",
"    ]. Topical agents, such as topical corticosteroids, should also be stopped one to two weeks in advance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Photopatch testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photopatch testing is useful in patients in whom a topical photoallergen is suspected (photoallergy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H25#H25\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Photoallergy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two identical sets of potential photoallergens are placed on the patient's back. After 24 hours, one set is removed and that site is irradiated with UVA at the dose of 5 to 10",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    The site is covered again, and 24 hours later, both the irradiated and control test sites are examined for reactions. A reaction to a specific photoallergen in the irradiated site, but not the control site, indicates a photoallergy. A similar reaction in both sites suggests a non-photo-induced allergic contact dermatitis.",
"   </p>",
"   <p>",
"    Although phototesting and photopatch testing are relatively simple procedures, they are most often performed in specialized centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PHOTOPROTECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H471504567\">",
"    <span class=\"h2\">",
"     Sun avoidance",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoidance of midday sun (between 10 am and 4 pm)",
"     </li>",
"     <li>",
"      Protective clothing: long sleeved shirts and pants, broad brim hats",
"     </li>",
"     <li>",
"      Window films that block UVR for cars and homes",
"     </li>",
"     <li>",
"      Broad spectrum sunscreen (protects against both UVA and UVB)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sun avoidance and protective clothing should be emphasized as important measures of photoprotection for patients with photosensitivity disorders. Sunscreen alone is not sufficient and should be used as an adjunct to other methods of sun protection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33447?source=see_link\">",
"     \"Selection of sunscreen and sun-protective measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are sensitive to radiation in the UVA range, it should be noted that substantial amounts of UVA are present in the morning and late afternoon, as well as midday. Because UVA can penetrate window glass, the very photosensitive patient may even have difficulty indoors and in a car.",
"   </p>",
"   <p>",
"    Protective clothing such as long sleeves and broad brim hats should be worn while outdoors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/7\">",
"     7",
"    </a>",
"    ]. Fabrics that are tightly woven, thick, or dark-colored are useful for protection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/8\">",
"     8",
"    </a>",
"    ]. Clothing developed for photosensitive individuals is commercially available from specialty companies. Clothing treated with broad-spectrum ultraviolet absorbers is also available.",
"   </p>",
"   <p>",
"    Window films that block UVA and some visible light can also be purchased for use in cars or homes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H471504575\">",
"    <span class=\"h2\">",
"     Sunscreen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sunscreen is important for daily use for patients with photosensitivity, particularly those with photosensitivity in the ultraviolet range. Sunscreens are divided into chemical (organic) and physical (inorganic) products. Chemical sunscreens provide protection in the ultraviolet range. Physical sunscreens have the ability to block both ultraviolet radiation and some visible light. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33447?source=see_link\">",
"     \"Selection of sunscreen and sun-protective measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with photosensitivity who have reduced MEDs to UVA should be advised to use a broad spectrum sunscreen with a minimum sun protection factor (SPF) of 30. &nbsp;",
"   </p>",
"   <p>",
"    The effectiveness of sun protection depends on the severity of photosensitivity and how well patients adhere to sun protective guidelines. Patients with more severe cases of photosensitivity may not respond to sun protection alone and will likely require other treatment modalities, depending on their specific diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118084\">",
"    <span class=\"h3\">",
"     Chemical sunscreens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The active ingredients in chemical sunscreens work by absorbing ultraviolet radiation and possess varying ultraviolet absorption spectra. A specific recommendation of a sunscreen with the most effective ingredients can be made if the action spectrum of the photodermatosis (UVA versus UVB) is known [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/10\">",
"     10",
"    </a>",
"    ]. Examples of chemical sunscreens that absorb within the UVB range include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cinnamates",
"     </li>",
"     <li>",
"      Salicylates",
"     </li>",
"     <li>",
"      Benzophenones",
"     </li>",
"     <li>",
"      Octocrylene",
"     </li>",
"     <li>",
"      Drometrizole trisiloxane (Mexoryl XL; not available in the US)",
"     </li>",
"     <li>",
"      Methylene-bis-benzotriazolyl tetramethylbutylphenol (Tinosorb M; not available in the US)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of chemical sunscreens that absorb within the UVA range include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Benzophenones (absorb short wavelengths of UVA)",
"     </li>",
"     <li>",
"      Avobenzone (photo-stabilized with octocrylene)",
"     </li>",
"     <li>",
"      Menthyl anthranilate",
"     </li>",
"     <li>",
"      Ecamsule (Mexoryl SX)",
"     </li>",
"     <li>",
"      Drometrizole trisiloxane (Mexoryl XL; not available in the US)",
"     </li>",
"     <li>",
"      Methylene-bis-benzotriazolyl tetramethylbutylphenol (Tinosorb M; not available in the US)",
"     </li>",
"     <li>",
"      Bis-ethylhexyloxyphenol methoxyphenyl triazine (Tinosorb S; not available in the US)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Products containing photostabilized avobenzone or ecamsule (Mexoryl SX) have been available in the US since 2006 and offer improved protection against UVA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Examples of products containing these agents are provided (",
"    <a class=\"graphic graphic_table graphicRef58215 \" href=\"UTD.htm?8/51/9019\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Tinosorb M is a broad-spectrum sunscreen that has both the absorptive properties of a chemical sunscreen and the light-scattering properties of a physical sunscreen. It is not available in the US.",
"   </p>",
"   <p>",
"    Chemical sunscreens may cause allergic contact dermatitis or photoallergic reactions in some patients. For patients with allergies to chemical sunscreens, physical sunscreens containing titanium dioxide or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    are alternatives for protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118091\">",
"    <span class=\"h3\">",
"     Physical sunscreens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical blocker (inorganic) sunscreens, such as titanium dioxide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    , work by reflecting and scattering ultraviolet and visible radiation. The large particle size of these ingredients makes them opaque and enables them to block some visible light, but may make them cosmetically unacceptable to patients. As a result, non-opaque, micronized formulations of titanium and zinc oxide have been developed. However, once micronized, the ingredients are less capable of scattering visible light and the longer wavelengths of UVA. Patients with visible light-sensitive photodermatoses utilizing physical blocker sunscreens as an adjunct to sun avoidance and sun-protective clothing should use the opaque, non-micronized formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27142/abstract/13\">",
"     13",
"    </a>",
"    ]. Examples of products containing these agents are provided (",
"    <a class=\"graphic graphic_table graphicRef58215 \" href=\"UTD.htm?8/51/9019\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Photosensitivity is an abnormal response to ultraviolet radiation or visible light which underlies many different cutaneous disorders termed \"photodermatoses\". The action spectra implicated in photodermatoses include ultraviolet and visible light. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Photobiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation of patients with photosensitivity disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of a photosensitivity disorder is primarily based upon obtaining a history and performing a skin examination. The age of onset, timeline of the eruption, family history, medication history, and appearance of the lesions are invaluable for narrowing the differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef57800 \" href=\"UTD.htm?15/1/15390\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Patient history'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation may include ANA, anti-dsDNA, anti-Ro (SSA), and anti-La (SSB) titers and porphyrin studies based upon a clinical suspicion of lupus erythematosus or porphyria. Skin biopsy can be helpful when correlated with clinical findings. Phototesting to determine the minimal erythema dose (MED) and action spectrum can narrow the differential diagnosis. Photopatch testing is useful in patients in whom a topical photoallergen is suspected. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Photoprotection via sun avoidance and sun-protective clothing is essential. Broad-spectrum (UVA and UVB) sunscreens are useful but may not adequately protect patients when used alone. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Photoprotection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with photosensitivity in the UV spectrum should apply broad-spectrum (UVA and UVB) sunscreens with a minimum SPF of 30. Products containing photostabilized avobenzone or ecamsule (Mexoryl SX) offer improved protection against UVA. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Photoprotection'",
"      </a>",
"      above.) Sunscreens that contain non-micronized",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      and titanium dioxide also provide broad spectrum photoprotection and are another option.",
"     </li>",
"     <li>",
"      For patients with visible light sensitivity, primary protection is provided by sun avoidance and photoprotective clothing. When skin exposure to sunlight is unavoidable, patients should use a physical blocker sunscreen (titanium dioxide or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      ) in an opaque, non-micronized formulation, rather than a chemical sunscreen, which has no effect on visible light transmission. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Photoprotection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Photosensitivity diseases: principles of diagnosis and treatment, Harber LC, Bickers DR (Eds), BC Decker, Toronto 1989. p.18.",
"    </li>",
"    <li>",
"     Lim HW, Hawk JLM. Evaluation of the photosensitive patient. In: Photodermatology, Lim HW, Honigsmann H, Hawk JLM.  (Eds), Informa Healthcare, New York 2007. p.139.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27142/abstract/3\">",
"      Yashar SS, Lim HW. Classification and evaluation of photodermatoses. Dermatol Ther 2003; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27142/abstract/4\">",
"      Botto NC, Warshaw EM. Solar urticaria. J Am Acad Dermatol 2008; 59:909.",
"     </a>",
"    </li>",
"    <li>",
"     Tanew A, Ferguson J. Phototherapy and photochemotherapy of the idiopathic photodermatosis. In: Dermatological phototherapy and photodiagnostic methods, 2nd ed, Krutmann H, Honigsmann H, Elmets C.  (Eds), Springer-Verlag, 2009. p.119.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27142/abstract/6\">",
"      Roelandts R. The diagnosis of photosensitivity. Arch Dermatol 2000; 136:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27142/abstract/7\">",
"      Gies P. Photoprotection by clothing. Photodermatol Photoimmunol Photomed 2007; 23:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27142/abstract/8\">",
"      Lautenschlager S, Wulf HC, Pittelkow MR. Photoprotection. Lancet 2007; 370:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27142/abstract/9\">",
"      Dawe R, Russell S, Ferguson J. Borrowing from museums and industry: two photoprotective devices. Br J Dermatol 1996; 135:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27142/abstract/10\">",
"      Deleo V. Sunscreen use in photodermatoses. Dermatol Clin 2006; 24:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27142/abstract/11\">",
"      Fourtanier A, Moyal D, Seit&eacute; S. Sunscreens containing the broad-spectrum UVA absorber, Mexoryl SX, prevent the cutaneous detrimental effects of UV exposure: a review of clinical study results. Photodermatol Photoimmunol Photomed 2008; 24:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27142/abstract/12\">",
"      Forestier S. Rationale for sunscreen development. J Am Acad Dermatol 2008; 58:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27142/abstract/13\">",
"      Moseley H, Cameron H, MacLeod T, et al. New sunscreens confer improved protection for photosensitive patients in the blue light region. Br J Dermatol 2001; 145:789.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6620 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-B6EAAB5947-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27142=[""].join("\n");
var outline_f26_32_27142=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHOTOBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION OF PATIENTS WITH PHOTOSENSITIVITY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Phototesting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Photopatch testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PHOTOPROTECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H471504567\">",
"      Sun avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H471504575\">",
"      Sunscreen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H118084\">",
"      - Chemical sunscreens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H118091\">",
"      - Physical sunscreens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/6620\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/6620|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/8/15502\" title=\"figure 1\">",
"      Electromagnetic spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/6620|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/1/15390\" title=\"table 1\">",
"      Photosensitive disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/51/9019\" title=\"table 2\">",
"      Broad spectrum sunscreens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5801?source=related_link\">",
"      Congenital erythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20455?source=related_link\">",
"      Polymorphous light eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33447?source=related_link\">",
"      Selection of sunscreen and sun-protective measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_32_27143="Submucosal leiomyoma position";
var content_f26_32_27143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Submucosal leiomyma position: European Society of Hysteroscopy classification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 476px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The European hysteroscopic classification of submucous leiomyomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baggish, MS, Valle, RF, Guedj, H. Hysteroscopy: Visual Perspectives of Uterine Anatomy, Physiology and Pathology. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27143=[""].join("\n");
var outline_f26_32_27143=null;
var title_f26_32_27144="GAVE argon plasma Rx Endosc";
var content_f26_32_27144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54724%7EGAST%2F56249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54724%7EGAST%2F56249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric antral vascular ectasia (watermelon stomach)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 544px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serial endoscopic images of gastric antral vascular ectasia (\"watermelon stomach\"), that has been treated with argon plasma coagulation. The top row shows the original appearance of the lesions, and their appearance following initial treatment. The middle row shows the appearance following the first treatment session and after the second treatment session. The third row demonstrates the marked improvement following the first two treatment sessions, and the appearance after a third treatment session.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thermal coagulation of gastric antral vascular ectasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance after bipolar probe thermal coagulation of gastric antral vascular ectasia (watermelon stomach). Coagulation with the bipolar probe eventually obliterated the vascular ectasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha, MD and Dennis M Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27144=[""].join("\n");
var outline_f26_32_27144=null;
var title_f26_32_27145="Epidemiology and pathogenesis of Pseudomonas aeruginosa infection";
var content_f26_32_27145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/32/27145/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27145/contributors\">",
"     Souha S Kanj, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27145/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/32/27145/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27145/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/32/27145/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/32/27145/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/32/27145/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomonas aeruginosa, a gram-negative nonfermenting bacillus, is a much feared pathogen. The organism is common in the environment, especially in water, even contaminating distilled water [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]; it is also the cause of infections associated with hot tubs and contaminated contact lens solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Considerable attention is paid to P. aeruginosa as a potential pathogen in hospitals because:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reservoirs for infection can develop, especially in intensive care units, often associated with water in sinks or respiratory equipment.",
"     </li>",
"     <li>",
"      The organism displays a predilection for infecting immunocompromised hosts, including burn patients.",
"     </li>",
"     <li>",
"      P. aeruginosa is the most serious pathogen in ventilator-associated pneumonia (VAP).",
"     </li>",
"     <li>",
"      There is an increase in occurrence of P. aeruginosa strains with resistance to multiple antibiotics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology and pathogenesis of infections due to P. aeruginosa will be reviewed here. The clinical manifestations, diagnosis, and treatment of infections due to this organism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=see_link\">",
"     \"Pseudomonas aeruginosa pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14775?source=see_link\">",
"     \"Pseudomonas aeruginosa bacteremia and endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=see_link\">",
"     \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link\">",
"     \"Treatment of Pseudomonas aeruginosa infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomonas aeruginosa was first isolated from green pus by Gessard in 1882. It was subsequently found to be involved in a variety of human infections from neonatal sepsis and burn sepsis to acute and chronic lung infections. P. aeruginosa is distinguished as an opportunistic pathogen, causing infections in patients with physical, phagocytic, or immunologic defects in host defense mechanisms.",
"   </p>",
"   <p>",
"    Attesting to its wide ecologic range and broad survival capabilities, P. aeruginosa is also an important plant pathogen, affecting tobacco, tomatoes and lettuce; it can be found in most fresh water environments, including moist areas in hospitals. Historically, P. aeruginosa has been a major burn wound pathogen, an agent of bacteremia in neutropenic patients, and the most important pathogen in cystic fibrosis (CF) patients, since the introduction of antistaphylococcal drugs. However, these interesting associations have undergone considerable change, with a shift in the spectrum of the hosts who are now commonly infected by P. aeruginosa.",
"   </p>",
"   <p>",
"    P. aeruginosa is [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The second most common cause of nosocomial pneumonia (17 percent)",
"     </li>",
"     <li>",
"      The third most common cause of urinary tract infection (7 percent)",
"     </li>",
"     <li>",
"      The fourth most common cause of surgical site infection (8 percent)",
"     </li>",
"     <li>",
"      The seventh most frequently isolated pathogen from the bloodstream (2 percent)",
"     </li>",
"     <li>",
"      The fifth most common isolate (9 percent) overall from all sites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is the most widespread multidrug-resistant gram-negative pathogen causing pneumonia in hospitalized patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Neutropenia and burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the early 1980s, the role of P. aeruginosa in infections in febrile neutropenic patients has diminished in Western Europe and North America. This organism previously accounted for one-third to one-half of gram-negative bacteremia in these patients, but it is a much less frequent pathogen today. An exception to this general rule occurs in Japan, where P. aeruginosa continues to be the most common cause of gram-negative bacteremia in the neutropenic patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar trends have occurred in burn patients in Europe and North America. P. aeruginosa was the single most important cause of burn wound sepsis and infectious deaths following burns in the past, but there has been a reduction in infection due to this organism since the 1980s.",
"   </p>",
"   <p>",
"    The reasons for the above trends are not entirely clear, although the use of antibiotic regimens directed at pseudomonas may play a role. It is likely that incidence of pseudomonas infection in subpopulations of patients such as neutropenic and burn patients is highly complex and related to acquisition and host factors, which are poorly understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;By contrast, the incidence of P. aeruginosa infections in cystic fibrosis (CF) patients has not diminished. P. aeruginosa is the most common cause of respiratory failure in CF and is responsible for the death of the majority of these patients. Acquisition of P. aeruginosa begins early in childhood (median one year) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/7\">",
"     7",
"    </a>",
"    ]. It is believed that the organism is initially acquired from environmental sources, but patient-to-patient spread may also occur in clinics and families [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over time, a number of mutations occur in P. aeruginosa in the CF lung environment that promote persistence of the organism. In one study, for example, 11 of 30 CF patients were colonized with a hypermutable strain of P. aeruginosa that persisted for years in most cases; such hypermutable strains were not isolated from patients with acute P. aeruginosa infection who did not have CF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/10\">",
"     10",
"    </a>",
"    ]. These hypermutable strains tend to be multidrug resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] and accumulate over time, often with the loss of virulence traits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/11\">",
"     11",
"    </a>",
"    ]. Interestingly, these adaptations are associated with reduced organism survival in a typical environmental habitat, such as tap water [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/11\">",
"     11",
"    </a>",
"    ]. Nonmutated strains with maintained virulence represent a minority of organisms.",
"   </p>",
"   <p>",
"    The initial acquisition of P. aeruginosa in the CF lung is with nonmucoid strains and occurs early in life (median one year) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/7\">",
"     7",
"    </a>",
"    ]. Over time (median 11 years), there is a transition to a mucoid phenotype that is associated with deterioration in cough scores, chest x-ray scores, and pulmonary function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other nosocomial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of P. aeruginosa as a cause of morbidity and mortality in ventilator-associated pneumonia (VAP) cannot be overstated. P. aeruginosa is among the most common causes of VAP and carries the highest mortality among hospital acquired infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/12\">",
"     12",
"    </a>",
"    ]. This fact has remained unchanged despite infection control policies that have tried to control this serious complication of medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    P. aeruginosa is also a significant pathogen in other types of lung infection. Patients with bronchiectasis eventually harbor multidrug resistant P. aeruginosa as the final pathogen.",
"   </p>",
"   <p>",
"    Pseudomonas continues to be a frequent cause of nosocomial bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/13-15\">",
"     13-15",
"    </a>",
"    ], wound and urinary tract infections, with occasional involvement of other sites following surgery (eg, gram-negative meningitis, sternal osteomyelitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/16\">",
"     16",
"    </a>",
"    ]. The role of antibiotics in the proliferation of P. aeruginosa in the hospital has also become clear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nosocomial outbreaks have been described due to faulty or unclean medical equipment or products, environmental or personnel reservoirs, and cross-contamination within the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. One of the largest outbreaks involved 231 patients in 24 hospitals in Norway; the major clinical manifestations were pneumonia and sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/18\">",
"     18",
"    </a>",
"    ]. The cause of the outbreak was contamination of moist mouth swabs during production. The in-hospital mortality rate was 31 percent, occurring only in patients with severe underlying disease. Contamination of medical equipment may also cause pseudo-outbreaks, as illustrated by a report of isolation of extremely drug-resistant P. aeruginosa from the urine of both hospitalized and ambulatory patients due to contamination of an automated urine analyzer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/21\">",
"     21",
"    </a>",
"    ]. These reports highlight the importance of the environmental cleaning component of infection control in preventing such infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H15#H15\">",
"     \"General principles of infection control\", section on 'Environmental cleaning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Community-acquired infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been increasing recognition of P. aeruginosa as a cause of community acquired infections, including folliculitis (due to hot tubs, whirlpools, or contaminated sponges) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/3,22,23\">",
"     3,22,23",
"    </a>",
"    ], pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/24\">",
"     24",
"    </a>",
"    ], puncture wound osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/25\">",
"     25",
"    </a>",
"    ], endocarditis in injection drug users [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], otitis externa after swimming in fresh water lakes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/28\">",
"     28",
"    </a>",
"    ], peritonitis or exit site infection in patients undergoing continuous ambulatory peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], and community-acquired bacteremia and pneumonia in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa displays panoply of virulence factors, more than those encountered in other pathogens such as group A streptococcus and Staphylococcus aureus. It produces a large number of toxins and surface components usually associated with virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], many of which have been studied in detail. While each of these toxins and surface components may show a deleterious effect in cell lines or even in an animal model, the role of many of these putative virulence factors remains unproven in humans.",
"   </p>",
"   <p>",
"    In contrast to most other bacteria, P. aeruginosa has two modes of virulence expression, resulting in at least two forms of distinct pathogenetic behavior.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It can remain confined to the lungs as a chronic, indolent colonizer as occurs in CF",
"     </li>",
"     <li>",
"      It can invade tissues causing pneumonia or bacteremia, with their potential complications of septic shock and death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic infection in cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CF die from respiratory failure because of a gradual loss of lung function. This results from the chronic inflammatory process perpetuated by P. aeruginosa, which colonizes the lung for periods of up to 40 years. The inflammation is triggered by the host response to the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/37\">",
"     37",
"    </a>",
"    ], not by tissue invasion. It may be argued that there is no expression of virulence in this setting and that the inflammation is simply a bystander reaction by the host to the presence of an organism in the airways. However, the fact that P. aeruginosa persists in the airways to the exclusion of most other bacteria suggests that there is active expression of specific genes to maintain this tropism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link&amp;anchor=H1531054#H1531054\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\", section on 'Pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genetic adaptation of P. aeruginosa to the airways of cystic fibrosis patients is illustrated by a detailed, whole genome analysis of P. aeruginosa isolates from a CF patient during eight years of infection that found virulence factors that are required for the initiation of acute infections are selected against during subsequent chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Persistence of the organism in the airways",
"    </span>",
"    &nbsp;&mdash;&nbsp;An examination of P. aeruginosa organisms isolated from this chronic state of colonization in patients with CF frequently shows the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Downregulation of the production of toxins [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Loss of lipopolysaccharides \"O\" side chains [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Expression of an alginate coat that probably protects against phagocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/41,42\">",
"       41,42",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H9635378\">",
"       'Mucoid phenotype'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Frequent loss of the flagellum and pili [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To explain these changes, one has to resort to evolutionary arguments, since conventional wisdom of pathogenesis dictates that an organism must express its virulence factors for disease to occur. There are two possible explanations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The immunologic response to these virulence factors allows the survival of only those strains that have mutated to phenotypes that evade the host immune mechanisms in the lungs. The observation that P. aeruginosa flagellin synthesis is downregulated in the CF lung, would then represent an adaptive response by the organism to avoid detection by host defense mechanisms, as flagellin is highly immunogenic and subject to detection by host pattern recognition receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The virulence factors are no longer needed for chronic colonization and random mutations in the genes that are responsible for virulence factor expression have occurred, leading to their loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While mutations could explain why host defenses do not eradicate the organisms, one would guess that there must have been a stage in which organisms of the normal phenotype were able to persist in the face of intact host defense mechanisms. The best explanation for this persistence may be defects in mucociliary clearance, as well as host killing of bacteria in CF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9635348\">",
"    <span class=\"h4\">",
"     Decreased bacterial killing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is now a body of literature that proposes that the CF lung shows decreased bacterial killing. This abnormality may be related in part to the high chloride concentrations in pulmonary secretions (CFTR is a chloride channel), since it can be reversed by a low chloride environment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/46\">",
"     46",
"    </a>",
"    ]. Among the defects induced by a high chloride environment are inactivation of beta-defensins, antimicrobial peptides secreted by respiratory epithelia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], increased release of inflammatory mediators by neutrophils, and diminished neutrophil killing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these defects in the CF patient do not explain the selection of P. aeruginosa as a pathogen rather than other bacteria. The predisposition to pseudomonas infection in patients with CF may be due in part to impaired clearance directly related to the defect in CFTR [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Consistent with this hypothesis is the observation that CFTR-knockout mice have an impaired ability to control pseudomonas lung infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. This is characterized by increased binding of P. aeruginosa to respiratory epithelial cells, an effect that can be reversed by CFTR gene transfer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9635371\">",
"    <span class=\"h4\">",
"     Biofilm formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biofilm or microcolony formation in P. aeruginosa may account for the ability of this organism to persist in the CF patient. These are adherent aggregates of bacterial cells that form on surfaces, including human tissue. Organisms contained in the biofilm are resistant to antibiotic treatment, which contributes to their ability to persist in chronic infection states. An in vitro study of P. aeruginosa identified that subinhibitory concentrations of aminoglycoside antibiotics induce biofilm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/54\">",
"     54",
"    </a>",
"    ]. A P. aeruginosa gene (aminoglycoside response regulator [arr]) was essential for this induction and contributed to biofilm-specific aminoglycoside resistance. Biofilm formation can be a specific, defensive reaction to the presence of antibiotics, a mechanism that may be responsible for the differences in therapeutic outcome in CF patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    aerosols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9635378\">",
"    <span class=\"h4\">",
"     Mucoid phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;During prolonged colonization, P. aeruginosa isolates often convert to a mucoid phenotype through production of the polysaccharide alginate. Alginate production contributes to biofilm growth, decreased clearance by host immune responses, and tissue damage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/55\">",
"     55",
"    </a>",
"    ]. One study demonstrated that alginate production was increased when the organisms were present in the relatively anaerobic environment of CF mucous [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/56\">",
"     56",
"    </a>",
"    ]. This mucoid phenotype is seen infrequently in non-CF populations, but occurs in over 75 percent of P. aeruginosa isolated from patients with CF. Opsonic antibodies produced by the host in CF are unable to kill these mucoid organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with CF, women are colonized with mucoid P. aeruginosa more frequently and earlier in chronic infection than men. Estrogen production appears to be directly related to this finding, as illustrated by a study in which exposure to estrogens induced alginate production in a non-mucoid strain of P. aeruginosa in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/58\">",
"     58",
"    </a>",
"    ]. In vivo, mucoid strains of P. aeruginosa were isolated more frequently during times of high estradiol production in six women with CF who were sampled throughout their menstrual cycles. Furthermore, among 23 women, mucoid P. aeruginosa accounted for 63 percent of strains isolated from pulmonary CF exacerbations that occurred during the follicular (high estradiol) phase of the menstrual cycle. In contrast, no strains isolated from exacerbations during the luteal phase (low estradiol) had the mucoid phenotype. Pulmonary exacerbations were also observed more frequently during the follicular phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Early airway colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of initial colonization are another area of great debate. There are at least three explanations for this early colonizing mechanism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The organism gains access to the airways and then attaches to cells via pili and flagella, which appear to be important for initial infection [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/59\">",
"       59",
"      </a>",
"      ]. This hypothesis suggests that there are more pilus receptors on CF cells or a greater response to pilin binding than on normal airway cells [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/60\">",
"       60",
"      </a>",
"      ]. Piliated organisms or purified pili lead to the production of interleukin (IL)-8 on airway epithelial cells; in one study, this response was four times higher in a CF cell line [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Wild-type CFTR may be a cellular receptor for P. aeruginosa; thus, the defective CFTR in CF might be unable to take up the organism and to clear it from the airways. In an in vitro study, murine cells expressing recombinant human wild-type CFTR ingested 30 to 100 times as many P. aeruginosa organisms as cells lacking CFTR or those expressing the mutant delta F508 CFTR protein seen in CF [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/51\">",
"       51",
"      </a>",
"      ]. The first extracellular domain of CFTR specifically binds to P. aeruginosa, which may be an important step in this process.",
"     </li>",
"     <li>",
"      The CF airways show mucous hypersecretion and a defect in mucociliary clearance that worsens with age; P. aeruginosa could take advantage of this situation because it is able to bind to the mucous and thus, be protected from phagocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These hypotheses are all testable. However, there is currently no animal model of chronic lung colonization to resolve this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Promotion of S. aureus colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa may promote S. aureus colonization in the CF lung. An exoproduct of P. aeruginosa (HQNO) protects S. aureus from killing by aminoglycosides and selects for small-colony variants of S. aureus that have stable aminoglycoside resistance and persist in chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/63\">",
"     63",
"    </a>",
"    ]. HQNO can be detected in the sputum of CF patients infected with P. aeruginosa but not in uninfected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link&amp;anchor=H2#H2\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\", section on 'Progression of pulmonary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute invasive P. aeruginosa infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa possesses a bewildering array of virulence factors implicated in acute infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/64\">",
"     64",
"    </a>",
"    ]. These include secreted products, exotoxins A, S, and U, elastase, alkaline protease, cytotoxins, phospholipase C, and phenazines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Cell bound organelles such as pili, flagella, and membrane bound lipopolysaccharide (LPS, endotoxin) have also been implicated in virulence.",
"   </p>",
"   <p>",
"    There is no single product that explains the organism's ability to cause disease and death, especially since it is an opportunistic pathogen whose virulence is expressed mainly in the immunocompromised host. A reasonable synthesis of the experimental work in this area is that different virulence factors play a role at different stages in the pathogenesis of invasive infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially, the organism requires an intact flagellum and motility to exert its maximum invasive effect in some animal models of infection. Strains lacking flagella are less capable of causing bacteremia and pneumonia in neonatal mice [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/68\">",
"     68",
"    </a>",
"    ] and of disseminating from burn wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative importance of the motility function of flagellum and a possible proinflammatory role of flagellin was examined in a lung model of acute P. aeruginosa infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/71\">",
"     71",
"    </a>",
"    ]. The findings suggested that flagellin is involved in early mortality, while loss of motility alone did not appear to affect virulence. Thus, the decreased virulence in strains lacking flagella in the neonatal mouse model cited above is more likely due to the absence of flagellin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=see_link\">",
"     \"Pseudomonas aeruginosa pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Lipopolysaccharide and toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;After invasion, LPS probably plays a role in disease similar to that proposed for other gram-negative pathogens. LPS protects the organism from the activity of complement in the bloodstream and triggers cytokine pathways, leading to the sepsis syndrome and septic shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to LPS, it has been proposed that the elaboration of toxins after invasion is responsible for some of the tissue damage. The role of toxins in the disease process has been difficult to determine, as there are no data incriminating a specific toxin, such as is found with diphtheria toxin or the staphylococcal and streptococcal shock toxins. In addition, mutants of P. aeruginosa lacking many of these toxins remain virulent.",
"   </p>",
"   <p>",
"    Thus, although toxins are probably not needed for the major disease syndromes encountered in most patients with P. aeruginosa infections, they may play a role in some localized infections such as in the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/72\">",
"     72",
"    </a>",
"    ] or lung [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/73,74\">",
"     73,74",
"    </a>",
"    ] and contribute to the severity of disease. This potential effect was illustrated in a study of P. aeruginosa strains isolated from 108 consecutive patients with lower respiratory or systemic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/73\">",
"     73",
"    </a>",
"    ]. Infection with a P. aeruginosa strain expressing the type III secreted toxins (eg, ExoS, ExoT, ExoU, or PcrV) was associated with a sixfold greater risk of death compared to infection with a strain that did not express these proteins (odds ratio, 6.2; 95% CI, 1.2-31.1). Expression of these toxins is associated with higher mortality in patients with P. aeruginosa bacteremia as well [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of infection may be limited by host factors. Experimental data suggest that host ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa dissemination mediated by the secreted toxin ExoT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/76\">",
"     76",
"    </a>",
"    ]. Ubiquitination leads to proteasomal degradation of the toxin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antibiotic resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fact that P. aeruginosa is both intrinsically resistant to a number of antibiotics and can acquire resistance during therapy assists in bacterial virulence. A number of mechanisms have been studied for the development of antibiotic resistance in P. aeruginosa including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AmpC beta-lactamase [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Downregulation of the outer membrane protein OprD, a carbapenem-specific porin [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/79,80\">",
"       79,80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Multi-drug efflux pumps [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/81-85\">",
"       81-85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ability of the organism to form a biofilm [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Possible transfer of a 16S rRNA methylase gene from Actinomycetes [",
"      <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/88\">",
"       88",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Tracking Resistance in the United States Today surveillance study examined the susceptibility patterns of 2394 clinical isolates of P. aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/89\">",
"     89",
"    </a>",
"    ]. From 2001 to 2003, the following rates of susceptibility were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"        Piperacillin",
"       </a>",
"       /tazobactam",
"      </span>",
"      &mdash; 86 percent",
"     </li>",
"     <li>",
"      Imipenem &mdash; 82 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      &mdash; 80 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      &mdash; 68 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      &mdash; 67 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       Gentamicin",
"      </a>",
"      &mdash; 73 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rates of multidrug resistance (resistance to &ge;3 antimicrobial agents) increased from 7.2 in 2001 to 9.9 percent in 2003. Resistance rates varied by region in the United States, with the highest rates of multidrug resistance in the East North Central and Mid-Atlantic regions.",
"   </p>",
"   <p>",
"    The use of locally derived antibiograms to predict susceptibility of individual antibiotics to P. aeruginosa may not be as reliable for patients who become infected during long hospital stays. In one study involving 3393 isolates of P. aeruginosa from a single tertiary care hospital, the utility of the hospital&rsquo;s antibiogram dropped as the length of time from admission to recovery of P. aeruginosa increased [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Better ways of administering antibiotics have been considered to overcome the increasing resistance patterns. In a pharmacodynamic analysis, high-dose, prolonged infusions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    had the highest probabilities of achieving bactericidal exposure for P. aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Potential for vaccine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Part of the impetus for studies of pathogenesis in P. aeruginosa infections is interest in the development of a vaccine to prevent infection in susceptible hosts or new antimicrobials for treatment of the organism. At present, no vaccines or specific antibiotics have resulted from this work, but development of vaccines against type III secretion system proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/92\">",
"     92",
"    </a>",
"    ], as well as LPS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/32/27145/abstract/93\">",
"     93",
"    </a>",
"    ] continues. The Pseudomonas genome sequence should provide further insights into the mechanisms of pathogenesis of P. aeruginosa infections and suggest new targets that can be exploited for vaccine development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19299002\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudomonas aeruginosa, a nonfermenting gram-negative bacillus, is prevalent in the environment, particularly in water, which can serve as a reservoir for infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      P. aeruginosa is a common cause of nosocomial pneumonia, urinary tract infection, and surgical site infection. It is now a less frequent cause of fever in patients with neutropenia, except in Japan, where it is the most common cause of gram-negative bacteremia in such patients. It remains the most important pathogen in patients with cystic fibrosis. P. aeruginosa is also associated with certain community-acquired infections following particular exposures (eg, water, puncture wounds, injection drug use). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with cystic fibrosis, chronic colonization with P. aeruginosa is associated with a downregulation of virulence factors and expression of a mucoid phenotype that likely protects against phagocytosis and opsonization. P. aeruginosa may also promote Staphylococcus aureus colonization in the lungs of patients with cystic fibrosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chronic infection in cystic fibrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strains that cause acute infections express a wide array of virulence factors. These include an intact flagellum, lipopolysaccharide, and secreted toxins. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute invasive P. aeruginosa infections'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      P. aeruginosa can develop resistance to antibiotics through a number of mechanisms, including expression of a beta-lactamase or efflux pumps and downregulation of outer membrane porins. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antibiotic resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/1\">",
"      Warburton DW, Bowen B, Konkle A. The survival and recovery of Pseudomonas aeruginosa and its effect upon salmonellae in water: methodology to test bottled water in Canada. Can J Microbiol 1994; 40:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/2\">",
"      Favero MS, Carson LA, Bond WW, Petersen NJ. Pseudomonas aeruginosa: growth in distilled water from hospitals. Science 1971; 173:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/3\">",
"      Silverman AR, Nieland ML. Hot tub dermatitis: a familial outbreak of Pseudomonas folliculitis. J Am Acad Dermatol 1983; 8:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/4\">",
"      Wilson LA, Schlitzer RL, Ahearn DG. Pseudomonas corneal ulcers associated with soft contact-lens wear. Am J Ophthalmol 1981; 92:546.",
"     </a>",
"    </li>",
"    <li>",
"     National Nosocomial Infection Surveillance (NNIS) system report: data summary from January 1992 through June 2003. file://www.cdc.gov/ncidod/dhqp/pdf (Accessed on December 03, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/6\">",
"      Funada H, Matsuda T. Changes in the incidence and etiological patterns of bacteremia associated with acute leukemia over a 25-year period. Intern Med 1998; 37:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/7\">",
"      Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/8\">",
"      Kosorok MR, Jalaluddin M, Farrell PM, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol 1998; 26:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/9\">",
"      Renders NH, Sijmons MA, van Belkum A, et al. Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings. Res Microbiol 1997; 148:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/10\">",
"      Oliver A, Cant&oacute;n R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/11\">",
"      Hogardt M, Hoboth C, Schmoldt S, et al. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis 2007; 195:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/12\">",
"      Crabtree TD, Gleason TG, Pruett TL, Sawyer RG. Trends in nosocomial pneumonia in surgical patients as we approach the 21st century: a prospective analysis. Am Surg 1999; 65:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/13\">",
"      Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/14\">",
"      Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/15\">",
"      Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/16\">",
"      Fong IW, Tomkins KB. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/17\">",
"      Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/18\">",
"      Iversen BG, Jacobsen T, Eriksen HM, et al. An outbreak of Pseudomonas aeruginosa infection caused by contaminated mouth swabs. Clin Infect Dis 2007; 44:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/19\">",
"      Srinivasan A, Wolfenden LL, Song X, et al. An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes. N Engl J Med 2003; 348:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Pseudomonas aeruginosa respiratory tract infections associated with contaminated ultrasound gel used for transesophageal echocardiography - Michigan, December 2011-January 2012. MMWR Morb Mortal Wkly Rep 2012; 61:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/21\">",
"      Hallin M, Deplano A, Roisin S, et al. Pseudo-outbreak of extremely drug-resistant pseudomonas aeruginosa urinary tract infections due to contamination of an automated urine analyzer. J Clin Microbiol 2012; 50:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/22\">",
"      Ratnam S, Hogan K, March SB, Butler RW. Whirlpool-associated folliculitis caused by Pseudomonas aeruginosa: report of an outbreak and review. J Clin Microbiol 1986; 23:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/23\">",
"      Maniatis AN, Karkavitsas C, Maniatis NA, et al. Pseudomonas aeruginosa folliculitis due to non-O:11 serogroups: acquisition through use of contaminated synthetic sponges. Clin Infect Dis 1995; 21:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/24\">",
"      Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/25\">",
"      Dixon RS, Sydnor CH 4th. Puncture wound pseudomonal osteomyelitis of the foot. J Foot Ankle Surg 1993; 32:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/26\">",
"      Silverman NA, Levitsky S, Mammana R. Acute endocarditis in drug addicts: surgical treatment for multiple valve infection. J Am Coll Cardiol 1984; 4:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/27\">",
"      Shekar R, Rice TW, Zierdt CH, Kallick CA. Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O11 among pentazocine and tripelennamine abusers in Chicago. J Infect Dis 1985; 151:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/28\">",
"      van Asperen IA, de Rover CM, Schijven JF, et al. Risk of otitis externa after swimming in recreational fresh water lakes containing Pseudomonas aeruginosa. BMJ 1995; 311:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/29\">",
"      Chan MK, Chan PC, Cheng IP, et al. Pseudomonas peritonitis in CAPD patients: characteristics and outcome of treatment. Nephrol Dial Transplant 1989; 4:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/30\">",
"      Kazmi HR, Raffone FD, Kliger AS, Finkelstein FO. Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1992; 2:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/31\">",
"      Lo CY, Chu WL, Wan KM, et al. Pseudomonas exit-site infections in CAPD patients: evolution and outcome of treatment. Perit Dial Int 1998; 18:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/32\">",
"      Baron AD, Hollander H. Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease. Am Rev Respir Dis 1993; 148:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/33\">",
"      Fichtenbaum CJ, Woeltje KF, Powderly WG. Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis 1994; 19:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/34\">",
"      Pollack M, Taylor NS, Callahan LT 3rd. Exotoxin production by clinical isolates of pseudomonas aeruginosa. Infect Immun 1977; 15:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/35\">",
"      Somerville G, Mikoryak CA, Reitzer L. Physiological characterization of Pseudomonas aeruginosa during exotoxin A synthesis: glutamate, iron limitation, and aconitase activity. J Bacteriol 1999; 181:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/36\">",
"      Kadurugamuwa JL, Beveridge TJ. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother 1997; 40:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/37\">",
"      Fick RB Jr, Sonoda F, Hornick DB. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway. Semin Respir Infect 1992; 7:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/38\">",
"      Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 2006; 103:8487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/39\">",
"      Raivio TL, Ujack EE, Rabin HR, Storey DG. Association between transcript levels of the Pseudomonas aeruginosa regA, regB, and toxA genes in sputa of cystic fibrosis patients. Infect Immun 1994; 62:3506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/40\">",
"      Hancock RE, Mutharia LM, Chan L, et al. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun 1983; 42:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/41\">",
"      Mathee K, Ciofu O, Sternberg C, et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999; 145 ( Pt 6):1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/42\">",
"      Boucher JC, Yu H, Mudd MH, Deretic V. Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 1997; 65:3838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/43\">",
"      Pier GB, Meluleni G, Neuger E. A murine model of chronic mucosal colonization by Pseudomonas aeruginosa. Infect Immun 1992; 60:4768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/44\">",
"      Mahenthiralingam E, Campbell ME, Speert DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 1994; 62:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/45\">",
"      Wolfgang MC, Jyot J, Goodman AL, et al. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc Natl Acad Sci U S A 2004; 101:6664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/46\">",
"      Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/47\">",
"      Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/48\">",
"      Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998; 102:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/49\">",
"      Tager AM, Wu J, Vermeulen MW. The effect of chloride concentration on human neutrophil functions: potential relevance to cystic fibrosis. Am J Respir Cell Mol Biol 1998; 19:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/50\">",
"      Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996; 271:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/51\">",
"      Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A 1997; 94:12088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/52\">",
"      Gosselin D, Stevenson MM, Cowley EA, et al. Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa. Am J Respir Crit Care Med 1998; 157:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/53\">",
"      Davies JC, Stern M, Dewar A, et al. CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. Am J Respir Cell Mol Biol 1997; 16:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/54\">",
"      Hoffman LR, D'Argenio DA, MacCoss MJ, et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/55\">",
"      Song Z, Wu H, Ciofu O, et al. Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. J Med Microbiol 2003; 52:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/56\">",
"      Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/57\">",
"      Meluleni GJ, Grout M, Evans DJ, Pier GB. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol 1995; 155:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/58\">",
"      Chotirmall SH, Smith SG, Gunaratnam C, et al. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med 2012; 366:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/59\">",
"      DiMango E, Zar HJ, Bryan R, Prince A. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 1995; 96:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/60\">",
"      Cervin MA, Simpson DA, Smith AL, Lory S. Differences in eucaryotic cell binding of Pseudomonas. Microb Pathog 1994; 17:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/61\">",
"      Vishwanath S, Ramphal R. Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun 1984; 45:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/62\">",
"      Vishwanath S, Ramphal R, Guay CM, et al. Respiratory-mucin inhibition of the opsonophagocytic killing of Pseudomonas aeruginosa. Infect Immun 1988; 56:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/63\">",
"      Hoffman LR, D&eacute;ziel E, D'Argenio DA, et al. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 2006; 103:19890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/64\">",
"      Tan MW, Rahme LG, Sternberg JA, et al. Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. Proc Natl Acad Sci U S A 1999; 96:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/65\">",
"      Mahajan-Miklos S, Tan MW, Rahme LG, Ausubel FM. Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa-Caenorhabditis elegans pathogenesis model. Cell 1999; 96:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/66\">",
"      Kamath S, Kapatral V, Chakrabarty AM. Cellular function of elastase in Pseudomonas aeruginosa: role in the cleavage of nucleoside diphosphate kinase and in alginate synthesis. Mol Microbiol 1998; 30:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/67\">",
"      Matsumoto T, Tateda K, Furuya N, et al. Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice. J Med Microbiol 1998; 47:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/68\">",
"      Feldman M, Bryan R, Rajan S, et al. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 1998; 66:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/69\">",
"      Drake D, Montie TC. Flagella, motility and invasive virulence of Pseudomonas aeruginosa. J Gen Microbiol 1988; 134:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/70\">",
"      Arora SK, Neely AN, Blair B, et al. Role of motility and flagellin glycosylation in the pathogenesis of Pseudomonas aeruginosa burn wound infections. Infect Immun 2005; 73:4395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/71\">",
"      Balloy V, Verma A, Kuravi S, et al. The role of flagellin versus motility in acute lung disease caused by Pseudomonas aeruginosa. J Infect Dis 2007; 196:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/72\">",
"      Fleiszig SM, Zaidi TS, Preston MJ, et al. Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa. Infect Immun 1996; 64:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/73\">",
"      Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/74\">",
"      Finck-Barban&ccedil;on V, Goranson J, Zhu L, et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 1997; 25:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/75\">",
"      El-Solh AA, Hattemer A, Hauser AR, et al. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 2012; 40:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/76\">",
"      Balachandran P, Dragone L, Garrity-Ryan L, et al. The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence. J Clin Invest 2007; 117:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/77\">",
"      Livermore DM. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/78\">",
"      Masuda N, Gotoh N, Ishii C, et al. Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/79\">",
"      Pai H, Kim J, Kim J, et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/80\">",
"      K&ouml;hler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/81\">",
"      Aires JR, K&ouml;hler T, Nikaido H, Pl&eacute;siat P. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 1999; 43:2624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/82\">",
"      De Kievit TR, Parkins MD, Gillis RJ, et al. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2001; 45:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/83\">",
"      Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2003; 47:3202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/84\">",
"      Hocquet D, Bertrand X, K&ouml;hler T, et al. Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrob Agents Chemother 2003; 47:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/85\">",
"      Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/86\">",
"      Walters MC 3rd, Roe F, Bugnicourt A, et al. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/87\">",
"      Mah TF, Pitts B, Pellock B, et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/88\">",
"      Yokoyama K, Doi Y, Yamane K, et al. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 2003; 362:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/89\">",
"      Karlowsky JA, Jones ME, Thornsberry C, et al. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 2005; 40 Suppl 2:S89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/90\">",
"      Anderson DJ, Miller B, Marfatia R, Drew R. Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation. Infect Control Hosp Epidemiol 2012; 33:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/91\">",
"      Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010; 32:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/92\">",
"      Frank DW, Vallis A, Wiener-Kronish JP, et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002; 186:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/32/27145/abstract/93\">",
"      DiGiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect Immun 2004; 72:7012.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3142 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27145=[""].join("\n");
var outline_f26_32_27145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19299002\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Neutropenia and burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other nosocomial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Community-acquired infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic infection in cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Persistence of the organism in the airways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9635348\">",
"      Decreased bacterial killing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9635371\">",
"      Biofilm formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9635378\">",
"      Mucoid phenotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Early airway colonization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Promotion of S. aureus colonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute invasive P. aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Invasion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Lipopolysaccharide and toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antibiotic resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Potential for vaccine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19299002\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14775?source=related_link\">",
"      Pseudomonas aeruginosa bacteremia and endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=related_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=related_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=related_link\">",
"      Treatment of Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_32_27146="Pemphigus vulgaris biopsy";
var content_f26_32_27146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60749%7EDERM%2F57313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60749%7EDERM%2F57313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic specimen of a bullous lesion in a patient with pemphigus vulgaris demonstrates the characteristic loss of cohesion between epidermal cells (acantholysis) with an intact basement membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus foliaceus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blister formation within the superficial granular layer in pemphigus foliaceus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27146=[""].join("\n");
var outline_f26_32_27146=null;
var title_f26_32_27147="Energy requirements premature";
var content_f26_32_27147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated daily energy requirements for growing premature infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Kcal/kg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resting energy expenditure",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        Resting metabolic rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activity",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        30 percent above resting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold stress",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        Thermoregulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synthetic effect of feeding",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        Dietary thermogenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fecal loss",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        10 percent of intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        Calories stored",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total caloric requirement",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         120",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Sinclair JC. Clin Obstet Gynecol 1971; 14:840.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27147=[""].join("\n");
var outline_f26_32_27147=null;
var title_f26_32_27148="Cosmeceuticals";
var content_f26_32_27148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cosmeceuticals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cosmeceuticals",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proposed mechanism of action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Antioxidants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Niacinamide (vitamin B3)",
"       </td>",
"       <td>",
"        Reduces transepidermal water loss, inhibits melanosome transfer, and increases collagen production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ascorbic acid (Vitamin C)",
"       </td>",
"       <td>",
"        Protects from UVA-induced oxidative damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coenzyme Q10",
"       </td>",
"       <td>",
"        Protects from UVA-induced oxidative damage, suppresses the expression of UVA-induced collagenase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin E",
"       </td>",
"       <td>",
"        Reduces UV induced erythema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retinyl esters, retinol, retinaldehyde, oxoretinoids",
"       </td>",
"       <td>",
"        Reduce matrix metalloproteinases, promote collagen production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alpha-lipoic acid",
"       </td>",
"       <td>",
"        Acts as a scavenger of reactive oxygen species, prevents lipid peroxidation, has antiinflammatory properties, and acts as an exfoliant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Hydroxyacids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alpha hydroxy acids (glycolic acid, lactic acid, citric acid, malic acid)",
"        <br/>",
"        Beta hydroxy acids (salicylic acid)",
"       </td>",
"       <td>",
"        Reduce corneocyte adhesion, increase exfoliation, improve stratum corneum hydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Plant extracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Green tea polyphenolic epicatechins",
"       </td>",
"       <td>",
"        Inhibit UV-induced erythema, reduce the formation of cyclobutane pyrimidine dimers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Soy isoflavones (genistein and daidzein)",
"       </td>",
"       <td>",
"        Act as antioxidants and phytoestrogens, inhibit UV-stimulated production of matrix metalloproteinase and melanosome transfer to keratinocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grape seeds (polyphenols)",
"       </td>",
"       <td>",
"        Have antioxidant and antiinflammatory properties, promote wound healing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coffee berry (polyphenols, flavonoids, and flavonol glycosides)",
"       </td>",
"       <td>",
"        Neutralize free radicals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ginkgo biloba (polyphenols, flavonoids, and flavonol glycosides)",
"       </td>",
"       <td>",
"        Stimulate fibroblast proliferation and collagen production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ginseng (ginsenosides)",
"       </td>",
"       <td>",
"        Has antioxidant and antiinflammatory properties",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27148=[""].join("\n");
var outline_f26_32_27148=null;
var title_f26_32_27149="AASLD Rx chronic HBV recs";
var content_f26_32_27149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for treatment of chronic hepatitis B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        HBeAg",
"       </td>",
"       <td class=\"subtitle1\">",
"        HBV DNA (PCR)",
"       </td>",
"       <td class=\"subtitle1\">",
"        ALT",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment strategy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        +",
"       </td>",
"       <td rowspan=\"4\">",
"        &gt;20,000 int. units/mL",
"       </td>",
"       <td rowspan=\"4\">",
"        &le;2 x ULN",
"       </td>",
"       <td>",
"        Low efficacy with current treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Observe, consider treatment when ALT becomes elevated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider biopsy in persons &gt;40 years, ALT persistently high normal-2x ULN, or with family history of HCC.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider treatment if HBV DNA &gt;20,000 int. units/mL and biopsy shows moderate/severe inflammation or significant fibrosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"12\">",
"        +",
"       </td>",
"       <td rowspan=\"12\">",
"        &gt;20,000 int. units/mL",
"       </td>",
"       <td rowspan=\"12\">",
"        &gt;2 x ULN",
"       </td>",
"       <td>",
"        Observe for 3 to 6 months and treat if no spontaneous HBeAg loss.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider liver biopsy prior to treatment if compensated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immediate treatment if icteric or clinical decompensation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IFN&alpha;/pegIFN&alpha;, LAM, ADV, ETV, TDF or LdT may be used as initial therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ADV not preferred due to weak antiviral activity and high rate of resistance after first year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LAM and LdT not preferred due to high rate of drug resistance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        End-point of treatment - Seroconversion from HBeAg to anti-HBe.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Duration of therapy:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; IFN-&alpha;: 16 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; PegIFN-&alpha;: 48 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; LAM/ADV/ETV/LdT/TDF: minimum&nbsp;one year, continue for at least&nbsp;six months after HBeAg seroconversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IFN&alpha; nonresponders / contraindications to IFN&alpha;&rarr; TDF/ETV.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        -",
"       </td>",
"       <td rowspan=\"8\">",
"        &gt;2000 int. units/mL",
"       </td>",
"       <td rowspan=\"8\">",
"        &gt;2 x ULN",
"       </td>",
"       <td>",
"        IFN-&alpha; / peg IFN-&alpha;, LAM, ADV, ETV, TDF or LdT may be used as initial therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LAM and LdT not preferred due to high rate of drug resistance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ADV not preferred due to weak antiviral activity and high risk of resistance after first year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        End-point of treatment - not defined.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Duration of therapy:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; IFN-&alpha;/pegIFN-&alpha;:&nbsp;one year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; LAM/ADV/ETV/LdT/TDF: &gt;one year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IFN&alpha; nonresponders / contraindications to IFN-&alpha;&rarr; TDF/ETV.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &gt;2000 int. units/mL",
"       </td>",
"       <td>",
"        1-&gt;2 x ULN",
"       </td>",
"       <td>",
"        Consider liver biopsy and treat if liver biopsy shows moderate/severe necroinflammation or significant fibrosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &le;2000 int. units/mL",
"       </td>",
"       <td>",
"        &le;ULN",
"       </td>",
"       <td>",
"        Observe, treat if HBV DNA or ALT becomes higher.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        +/-",
"       </td>",
"       <td rowspan=\"5\">",
"        Detectable",
"       </td>",
"       <td rowspan=\"5\">",
"        Cirrhosis",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Compensated:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; HBV DNA &gt;2000 int. units/mL - Treat, LAM/ADV/ETV/LdT/TDF may be used as initial therapy. LAM and LdT not preferred due to high rate of drug resistance; ADV not preferred due to weak antiviral activity and high risk of resistance after first year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; HBV DNA &lt;2000 int. units/mL - Consider treatment if ALT elevated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Decompensated:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Coordinate treatment with transplant center, LAM (or LdT) +ADV, TDF, or ETV preferred. Refer for liver transplant.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        +/-",
"       </td>",
"       <td rowspan=\"2\">",
"        Undetectable",
"       </td>",
"       <td rowspan=\"2\">",
"        Cirrhosis",
"       </td>",
"       <td>",
"        Compensated: Observe.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decompensated: Refer for liver transplant.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALT: alanine aminotransferase; ULN: upper limit of normal; IFN&alpha;: interferon alpha; pegIFN-&alpha;: pegylated IFN-alpha; LAM: lamivudine; ADV: adefovir; ETV: entecavir; LdT: telbivudine; TDF: tenofovir disoproxil fumarate.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at file://publish.aasld.org/Pages/Default.aspx. Accessed September 8th 2009. Copyright &copy; 2009 American Association for the Study of Liver Diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27149=[""].join("\n");
var outline_f26_32_27149=null;
var title_f26_32_27150="Alcohol consumption mortality";
var content_f26_32_27150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Moderate alcohol intake reduces mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 426px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a middle-aged and elderly population study of 490,000 subjects, all-cause mortality and cardiovascular mortality were reduced with moderate alcohol consumption. However, mortality increased with intake greater than two drinks per day due to death from alcohol-related conditions and cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Thun MJ, Peto R, Lopez AD, et al. N Engl J Med 1997; 337:1705.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27150=[""].join("\n");
var outline_f26_32_27150=null;
var title_f26_32_27151="Detection of bolus movement";
var content_f26_32_27151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MI detected bolus movement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 389px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in intraluminal impedance during swallowing and reflux. A drop in impedance identifies bolus entry in a segment followed by a recovery once the bolus exits the impedance-measuring segment. Changes in impedance progressing from proximal to distally indicate antegrade bolus movement as seen during swallowing while changes in impedance progressing distally to proximally indicate retrograde bolus movement as seen during reflux.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Radu Tutuian, MD and Donald O Castell, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_32_27151=[""].join("\n");
var outline_f26_32_27151=null;
